Osborne Clarke advises naturalX Health Ventures on Series B investment in Function Health

Osborne Clarke has advised naturalX Health Ventures, – a EUR 100 Mio. VC focused on Consumer Health – on its investment as part of the oversubscribed Series B financing round in Function Health. The round totals USD 298 million and values the company at around USD 2.5 billion; other investors include, among others, Andreessen Horowitz, Redpoint, Battery Ventures, AGLAÉ Ventures, Alumni Ventures and NFDG.

Function Health is developing a novel, preventive health model for consumers. The starting point is a comprehensive panel of over 160 biomarkers that gives users insights into their metabolic, hormonal, cardiovascular and immunological health, thereby identifying health risks early through a simple test that might otherwise go undetected. With its Medical Intelligence Lab, Function Health is taking the next step: an AI‑powered platform integrates laboratory results, imaging, wearables, medical records and global research into a dynamic, personalised health model. The system learns continuously, detects patterns early and translates them into specific recommendations for action.

The company has now closed its oversubscribed Series B financing round: Alongside naturalX Health Ventures, Andreessen Horowitz, Redpoint, Battery Ventures, AGLAÉ Ventures, Alumni Ventures and NFDG are investing a total of USD 298 million, increasing Function Health’s valuation to around USD 2.5 billion.

“This is exactly the shift we believe in at naturalX: consumers are taking ownership of their wellbeing and becoming the CEOs of their own health. Function Health is building the health operating system for consumers and human health, not digitizing yesterday’s healthcare model but creating a new one proactive, data-rich, continuous, and deeply personalized”, commented naturalX Health Ventures.

The Osborne Clarke team that advised naturalX Health Ventures comprised Till‑Manuel Saur and Robert Marx (both Corporate/VC).